Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.44 |
| ▸ | GRIN1 known ✓ | Q05586 | 2/20 | 0.44 |
| ▸ | TTR known ✓ | P02766 | 1/20 | 0.41 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.40 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.40 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.40 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.40 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.52 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.52 |
| ▸ | TPMT | P51580 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | CASP1 | P29466 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL111202 | 0.97 | AKR1C4 (0.54) | AKR1C4AKR1C3AKR1C2AKR1C1TPMT | |
| SCHEMBL28392002 | 0.95 | AKR1C4 (0.52) | AKR1C4AKR1C3AKR1C2AKR1C1TPMT | |
| SCHEMBL1301827 | 0.95 | AKR1C4 (0.52) | AKR1C4AKR1C3AKR1C2AKR1C1TPMT | |
| SCHEMBL5878784 | 0.95 | AKR1C4 (0.52) | AKR1C4AKR1C3AKR1C2AKR1C1TPMT | |
| Urea SCHEMBL29192961 | 0.90 | AKR1C4 (0.48) | AKR1C4AKR1C3AKR1C2AKR1C1TPMT | |
| SCHEMBL5355330 | 0.83 | SPR (0.55) | AKR1C4AKR1C3AKR1C2AKR1C1TPMT | |
| SCHEMBL8467899 | 0.83 | AKR1C4 (0.63) | AKR1C4AKR1C3AKR1C2AKR1C1TPMT | |
| SCHEMBL29684531 | 0.83 | AKR1C4 (0.63) | AKR1C4AKR1C3AKR1C2AKR1C1TPMT | |
| Hydrochloric Acid SCHEMBL941982 | 0.82 | TTR (0.62) | TPMTTSHRSMN1; SMN2DPP4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5512605 | 0.82 | TTR (0.62) | TPMTTSHRSMN1; SMN2DPP4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023190392-A1 | MACRO-POLYMERIZATION INITIATOR AND METHOD FOR PORDUCING MACRO-POLYMERIZATION INITIATOR | 三井化学株式会社 | 2023-10-05 | — | — | WO | disclosed |
| US-8795939-B2 | Toner, and developer and image forming apparatus using the toner | RICOH COMPANY, LTD. (JP) | 2014-08-05 | — | — | US | disclosed |
| EP-1756042-B1 | SUBSTITUTED METHYL ARYL OR HETEROARYL AMIDE COMPOUNDS | RAQUALIA PHARMA INC (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-20130108950-A1 | TONER, AND DEVELOPER AND IMAGE FORMING APPARATUS USING THE TONER | RICOH COMPANY, LTD. (JP) | 2013-05-02 | — | — | US | disclosed |
| US-8084476-B2 | Substituted methyl aryl or heteroaryl amide compounds | RAQUALIA PHARMA INC. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-8034947-B2 | Pyridine oxide compound, and process for producing carboxylic acid derivative and optically active carboxylic acid derivative with the use of the same | TOKYO UNIVERSITY OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20100168179-A1 | 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTHILONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE IN PHARMACEUTICAL PREPARATIONS | KLAR ULRICH | 2010-07-01 | — | — | US | disclosed |
| US-7700621-B2 | E.g., 4-(2-methyl-3-oxo-hept-6-en-2-yl)-2,2-dimethyl-[1,3]-dioxane chemical intermediate; chemical/metabolic stabilization of microtubuli; antitumor, -carcinogenic agents; malignant melanoma, acute lymphocytic/myelocytic leukemia; angiogenesis inhibitors; antiinflammatory/-arthritic agents; psoriasis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-20 | — | — | US | disclosed |
| US-7645891-B2 | E.g., 4-(2-methyl-3-oxo-hept-6-en-2-yl)-2,2-dimethyl-[1,3]-dioxane chemical intermediate; chemical/metabolic stabilization of microtubuli; antitumor, -carcinogenic agents; malignant melanoma, acute lymphocytic/myelocytic leukemia; angiogenesis inhibitors; antiinflammatory/-arthritic agents; psoriasis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-01-12 | — | — | US | disclosed |
| EP-1173441-B1 | 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTHILONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE IN PHARMACEUTICAL PREPARATIONS | BAYER SCHERING PHARMA AG (DE) | 2009-08-26 | — | — | EP | disclosed |
| US-6624162-B2 | 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, Functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. | PFIZER INC. | 2003-09-23 | — | — | US | disclosed |
| US-6610736-B1 | Antitumor | SCHERING AG (DE) | 2003-08-26 | — | — | US | disclosed |
| US-20030144523-A1 | EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING SAME AND THEIR PHARMACEUTICAL USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-07-31 | — | — | US | disclosed |
| US-20030139460-A1 | 9-oxa-epothilon derivatives, method for the production and use thereof in pharmaceutical preparations | SCHERING AG (DE) | 2003-07-24 | — | — | US | disclosed |
| US-20030092699-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2003035649-A1 | IMIDAZOPYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS | PFIZER JAPAN INC. (JP) | 2003-05-01 | — | — | WO | disclosed |
| EP-1173441-A1 | 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTHILONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE IN PHARMACEUTICAL PREPARATIONS | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000066589-A1 | 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTHILONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE IN PHARMACEUTICAL PREPARATIONS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-11-09 | — | — | WO | disclosed |
| EP-0988297-A2 | PROCESS FOR PREPARING OPTICALLY ACTIVE PHENYLOXIRANE COMPOUNDS | Tanabe Seiyaku Co., Ltd. (JP) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998056762-A2 | PROCESS FOR PREPARING OPTICALLY ACTIVE PHENYLOXIRANE COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092699-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | HTR4, HRH4, HRH2 | DPP4 947/4885GRIN1 1172/4885TTR 3492/4885 |
| US-20100168179-A1 | 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTHILONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE IN PHARMACEUTICAL PREPARATIONS | TUBB6, CCNB1, TUBB | DPP4 4762/4885GRIN1 4513/4885TTR 1892/4885 |
| US-20030144523-A1 | EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING SAME AND THEIR PHARMACEUTICAL USE | TUBB1, TUBA1C, TUBB4A | DPP4 4617/4885GRIN1 4136/4885TTR 4109/4885 |
| US-20030139460-A1 | 9-oxa-epothilon derivatives, method for the production and use thereof in pharmaceutical preparations | TUBB4A, TUBB1, TUBB | DPP4 4553/4885GRIN1 4440/4885TTR 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.